Randomized trial of two fractionation schedules of myeloablative busulfan with fludarabine and cladribine in AML or MDS
{{output}}
Background: A myeloablative busulfan and fludarabine regimen that includes fractionating busulfan and extending its delivery time results in low toxicity, permitting its use in stem cell transplant recipients who would otherwise ... ...
